Literature DB >> 30827233

PI3K/Akt-Nrf2 and Anti-Inflammation Effect of Macrolides in Chronic Obstructive Pulmonary Disease.

Xuejiao Sun1, Lin Chen1, Zhiyi He2.   

Abstract

BACKGROUND: Chronic Obstructive Pulmonary Disease (COPD) is a systematic inflammatory disease, and smoking is an important risk factor for COPD. Macrolide can reduce COPD inflammation. However, the inflammatory mechanism of COPD remains unclear and the anti-inflammatory mechanism of Macrolide is complex and not exactly known.
METHODS: We read and analysed thirty-eight articles, including original articles and reviews.
RESULTS: The expression of Nrf2 was lower in COPD patients and might have a protective role against apoptosis caused by CSE-induced oxidative stress. Nrf2 may play an important role in COPD inflammation. Nrf2 is a key factor in downstream of PI3K/Akt and is involved in the regulation of oxidative stress and inflammatory response. Therefore, PI3K/Akt pathway may play an important role in the activation of Nrf2 and COPD inflammation. Macrolide reduces lung and systemic inflammation of COPD by regulating PI3K/Akt pathway.
CONCLUSION: This review indicates that PI3K/Ak-Nrf2 may play an important role in COPD inflammation and macrolides may reduce lung and systemic inflammation of COPD by regulating PI3K/Akt-Nrf2 pathway. However, many crucial and essential questions remain to be answered. Further understanding of the mechanisms of macrolide efficacy and PI3K/Akt-Nrf2-mediated inflammatory responses may provide a new clue for exploring COPD treatment in the future. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Nrf2 protein; PI3K/Akt pathway; chronic obstructive pulmonary disease; inflammation; macrolides; oxidative stress.

Mesh:

Substances:

Year:  2019        PMID: 30827233     DOI: 10.2174/1389200220666190227224748

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  21 in total

Review 1.  Pathological Mechanism and Targeted Drugs of COPD.

Authors:  Peng Guo; Rui Li; Tie Hua Piao; Chun Lan Wang; Xiao Lu Wu; Hong Yan Cai
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-07-12

2.  Dapagliflozin attenuates cholesterol overloading-induced injury in mice hepatocytes with type 2 diabetes mellitus (T2DM) via eliminating oxidative damages.

Authors:  Liu Yang; Dan Liu; Hongqin Yan; Kaixia Chen
Journal:  Cell Cycle       Date:  2022-01-31       Impact factor: 4.534

Review 3.  Evaluation of Naringenin as a Promising Treatment Option for COPD Based on Literature Review and Network Pharmacology.

Authors:  Zhen Chen; Pan Chen; Hao Wu; Rui Shi; Weiwei Su; Yonggang Wang; Peibo Li
Journal:  Biomolecules       Date:  2020-12-08

4.  Sinomenine activation of Nrf2 signaling prevents inflammation and cerebral injury in a mouse model of ischemic stroke.

Authors:  Fangfang Bi; Yiyong Zhang; Wenbo Liu; Keliang Xie
Journal:  Exp Ther Med       Date:  2021-04-18       Impact factor: 2.447

5.  PI3K/AKT signaling pathway: a possible target for adjuvant therapy in COVID-19.

Authors:  Mohammad Rafi Khezri
Journal:  Hum Cell       Date:  2021-01-11       Impact factor: 4.174

6.  Correlations among Pulmonary DJ-1, VDR and Nrf-2 in patients with Chronic Obstructive Pulmonary Disease: A Case-control Study.

Authors:  Ying Xiang; Lin Fu; Hui-Xian Xiang; Ling Zheng; Zhu-Xia Tan; Li-Xiang Wang; Wei Cao; De-Xiang Xu; Hui Zhao
Journal:  Int J Med Sci       Date:  2021-04-22       Impact factor: 3.738

Review 7.  Comparison of COVID-19 and Lung Cancer via Reactive Oxygen Species Signaling.

Authors:  Zilan Zhu; Ziyi Zheng; Jian Liu
Journal:  Front Oncol       Date:  2021-07-02       Impact factor: 6.244

8.  LncRNA CASC2 is involved in the development of chronic obstructive pulmonary disease via targeting miR-18a-5p/IGF1 axis.

Authors:  Panpan Liu; Huali Zhang; Haizhu Zeng; Yingxia Meng; Hongchang Gao; Meilan Zhang; Lei Zhao
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 4.031

Review 9.  Preventing the development of severe COVID-19 by modifying immunothrombosis.

Authors:  Gerwyn Morris; Chiara C Bortolasci; Basant K Puri; Lisa Olive; Wolfgang Marx; Adrienne O'Neil; Eugene Athan; Andre Carvalho; Michael Maes; Ken Walder; Michael Berk
Journal:  Life Sci       Date:  2020-10-20       Impact factor: 5.037

Review 10.  Progress in the mechanism and targeted drug therapy for COPD.

Authors:  Cuixue Wang; Jiedong Zhou; Jinquan Wang; Shujing Li; Atsushi Fukunaga; Junji Yodoi; Hai Tian
Journal:  Signal Transduct Target Ther       Date:  2020-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.